Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02532452 · ClinicalTrials.gov registry record · Phase 2
Third Party Viral Specific T-cells (VSTs)
A Phase 2 study of Viral Infection and Viral Reactivation, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 750
- Enrollment target
- 4
- Study locations
NCT02532452: Recruiting Phase 2 study of Viral Infection and Viral Reactivation, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT02532452 is a Phase 2 study of Viral Infection and Viral Reactivation that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 750 participants, above the 161-participant average among 11 other Viral Infection trials with a reported enrollment target (366% higher). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02532452, a Phase 2 study of Viral Infection and Viral Reactivation, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 750 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.
Primary Outcome
Of the patients who had a VST culture initiated, successful production of VST cells is defined as meeting the protocol-defined release criteria.
Conditions Studied
Interventions
- BIOLOGICAL Viral Specific VST Infusion
Study Locations (4)
Ohio
- Akron Children's Hospital - Akron
- University of Cincinnati Medical Center - Cincinnati
- Cincinnati Children's Hospital Medical Center - Cincinnati
- The Ohio State University Wexner Medical Center - James Cancer Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2015-09-02 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT02532452 shows while recruiting
NCT02532452 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, above the 161-participant average among 11 other Viral Infection trials with a reported enrollment target (366% higher).
The record links to 3 conditions, with Viral Infection appearing as the primary indexed condition, and to 1 intervention - of which Viral Specific VST Infusion is the first listed.
NCT02532452 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02532452 about?
NCT02532452 is a clinical study titled "Third Party Viral Specific T-cells (VSTs)". The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.
What is the current status of trial NCT02532452?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 750 participants. The study started on 2015-09-02. Estimated completion is 2027-12.
What conditions does trial NCT02532452 study?
This clinical trial studies the following conditions: Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host.
What interventions are being tested in trial NCT02532452?
The interventions under investigation include: Viral Specific VST Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT02532452?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02532452 being conducted?
This trial has 4 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Viral Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02532452's enrollment target sits among peer trials
750 1st of 11 the highest of 11 other Viral Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Viral Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant
RECRUITING · Phase 2
-
Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant
ACTIVE NOT RECRUITING · Phase 2
-
Smell Changes & Efficacy of Nasal Theophylline
COMPLETED · Phase 2
-
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
RECRUITING · Phase 1
-
Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis
RECRUITING · Phase 1
-
School Inner City Air Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- NCT04723095 · 750 participants
Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix
- NCT04845230 · 750 participants · NA
Fresh RX: NHS 2020
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI